GMA 10X
Alternative Names: GMA10XLatest Information Update: 20 Jan 2021
At a glance
- Originator Gmax Biopharm
- Class Hepatoprotectants; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 20 Jan 2021 GMA 10X is available for licensing as of 20 Jan 2021. http://www.gmaxbiopharm.com/job.html
- 20 Jan 2021 Preclinical trials in Non-alcoholic steatohepatitis in China (Parenteral) (Gmax Biopharm pipeline, January 2021)
- 20 Jan 2021 Preclinical trials in Obesity in China (Parenteral) (Gmax Biopharm pipeline, January 2021)